Market Overview

UPDATE: Deutsche Bank Raises PT on Tenet Healthcare Corp. on Continued Good Outlook

Related THC
Morgan Stanley Says Ebola Scare Could Defer Elective Surgeries In Texas
Conifer Health Solutions To Acquire SPi Healthcare For $235M , Company Says Purchase Should Be Complete In Q4 2014

In a report published Friday, Deutsche Bank reiterated its Buy rating on Tenet Healthcare Corp. (NYSE: THC), and raised its price target from $43.00 to $46.00.

Deutsche Bank noted, “We continue to believe an upside risk to THC's valuation is its Conifer segment, which is growing at a faster pace than the overall enterprise and could begin to differentiate THC's multiple once Conifer's stand-alone (non-THC) EBITDA is convincing enough to the market. Finally, we note that our valuation framework does not include THC's NOL, which provides an additional $3-4 of cushion to the valuation. Key risks include: Medicare/Medicaid cuts, implementation risks of PPACA, HCIT conversions, M&A integration, state exposures in Texas, Florida and California.”

Tenet Healthcare Corp. closed on Thursday at $41.76.

Latest Ratings for THC

DateFirmActionFromTo
Sep 2014Deutsche BankMaintainsBuy
Aug 2014Raymond JamesUpgradesMarket PerformOutperform
Aug 2014BarclaysMaintainsOverweight

View More Analyst Ratings for THC
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings

 

Related Articles (THC)

Around the Web, We're Loving...

Get Benzinga's Newsletters